Keywords: 3m-euro, grant, thrombogenics, develop, anti-vpac1, leuven, belgium-based
3.3M-euro grant for ThromboGenics to develop anti-VPAC1
Article | 09 March 2009
Leuven, Belgium-based ThromboGenics NV, a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, has been ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
